• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
  • A Review of Progress of Immunotherapy Drugs for Hodgkin’s Lymphoma PharmaSources/Yefenghong
    July 03, 2019
    The news widespread in the industry that Hengrui has received the pharmaceutical product registration approval for its anti-PD-1 camrelizumab has been confirmed recently. It took 24 days from the beginning of review to the receipt of approval on May 29.

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service